[Nexera Pharma Co., Ltd.]
Receives USD 35 million milestone from Neurocline due to positive Phase II clinical trial results for schizophrenia drug candidate NBI-1117568
*Nexera Pharma Co., Ltd.*
Press release: September 2, 2024
**
Receives USD 35 million milestone from Neurocline due to positive Phase II clinical trial results for schizophrenia drug candidate NBI-1117568
As announced on August 28, 2024, Nexera Pharma Co., Ltd. (formerly Sosei Group Co., Ltd., hereinafter referred to as the “Company”) is pleased to announce the successful completion of the Phase II clinical trial of NBI-1117568 in adults with schizophrenia. After achieving results and confirming that all pre-defined milestone acceptance requirements have been met, our partner Neurocrine
Biosciences
We would like to inform you that we will receive 35 million US dollars (approx. 5,068 million yen [US dollar = 144.80 yen]) from Neurocline Inc. (hereinafter referred to as “Neurocline”, Nasdaq: NBIX). This milestone is scheduled to be recorded as a lump-sum revenue in the third quarter of 2024.
NBI-1117568-SCZ2028 dose-finding study
So, 20 mg
Neurocrine plans to launch a Phase III clinical trial of NBI-1117568 in 2025, as the once-daily dose group met its primary endpoint and safety and tolerability were generally good in all dose groups. The intention is to start in the first half of this year. Our full announcement regarding the positive results of this study is available on August 28, 2024.
“Favorable results in Phase II clinical trial of schizophrenia drug candidate NBI-1117568, a collaborative program with Neurocrine” Please see